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Abstract: OBJECTIVES The objective of the study was to determine the change in quality of evidence
in updates of Cochrane reviews that were initially published between January 1, 2013 and June 30, 2014.
We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system
to document evidence quality. STUDY DESIGN AND SETTING We searched the Cochrane Database
of Systematic Reviews on March 20, 2020 to identify which of the reviews from the initial (2013/14)
sample had been updated. Using the same methods to determine the quality of evidence in the previous
analysis, we assessed the quality of evidence for the first-listed primary outcomes in the updated reviews.
RESULTS Of the 608 reviews in the original sample, 154 had been updated with and 151 contained
available data for both original and updated systematic reviews (24.8%). The updated reviews included:
15 (9.9%) with high-quality evidence, 56 (37.1%) with moderate-quality evidence, 47 (31.1%) with low-
quality evidence, and 33 (21.9%) with very low-quality evidence. No change in the GRADE quality of
evidence was found for most (103, 68.2%) of the updated reviews. The quality of evidence rating was
downgraded in 28 reviews (58.3%) and upgraded in 20 (41.7%), although only six reviews were promoted
to high quality. CONCLUSION Updated systematic reviews continued to suggest that only a minority
of outcomes for health care interventions are supported by high-quality evidence. The quality of the
evidence did not consistently improve or worsen in updated reviews.
DOI: https://doi.org/10.1016/j.jclinepi.2020.08.005





Howick, Jeremy; Koletsi, Despina; Pandis, Nikolaos; Fleming, Padhraig S; Loef, Martin; Walach, Harald;
Schmidt, Stefan; Ioannidis, John P A (2020). The quality of evidence for medical interventions does not




The quality of evidence for medical interventions does not improve or worsen: A Meta-
Epidemiological Study of Cochrane Reviews 
 
Jeremy Howick, PhD1, Despina Koletsi, DiplDS, Dr. med. dent2*, Nikolaos Pandis3, Padhraig 
S. Fleming, PhD4, Martin Loef, PhD5, Harald Walach, PhD5,6, Stefan Schmidt, PhD7, John 
P.A. Ioannidis, MD, DSc8 
 
1 Faculty of Philosophy, University of Oxford, Oxford OX2 6GG, United Kingdom 
2 Clinic of Orthodontics and Pediatric Dentistry, Center of Dental Medicine, University of 
Zurich, Switzerland 
*joint first author 
3 Department of Orthodontics and Dentofacial Orthopedics, School of Dental Medicine, 
Medical Faculty, University of Bern, Bern, Switzerland 
4 Institute of Dentistry, Queen Mary, University of London 
5 CHS-Institute, Berlin, Germany 
6 Poznan University of the Medical Sciences, Department of Pediatric Gastroenterlogy, 
Poznan, Poland 
7 Department of Psychosomatic Medicine and Psychotherapy, Medical Center, University of 
Freiburg 
8 Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data 
Science, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), 




Howick J, Koletsi D, Pandis N, Fleming PS, Loef M, Walach H, Schmidt S, Ioannidis JPA. 
The quality of evidence for medical interventions does not improve or worsen: a Meta-
Epidemiological Study of Cochrane Reviews. J Clin Epidemiol. 2020 Aug 10:S0895-




Correspondence to: Jeremy Howick, Faculty of Philosophy, University of Oxford, Oxford 





Open Science Framework: Howick, J., Koletsi, D., Fleming, P., Schmidt, S., Loef, M., 
Walach, H., … Ioannidis, J. (2020, March 30). Has the Quality of Evidence for Medical 




JH, (guarantor) JPAI conceived of the idea, JH wrote the first draft of the protocol, DK did 
the data extraction; JH, ML, PF, HW checked the extraction. DK and NP did the initial 




The writing of this protocol was not independently funded. 
 
Declaration of interest 





Background: A previous analysis of Cochrane Reviews published between January 1st, 
2013 and June 30th, 2014 found that only 13.5% reported high quality evidence for the 
intervention according the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) system. 31.7% had low level, and 24% revealed very low level of 
evidence. Many of these reviews have been updated, and it is unknown whether the updated 
reviews report a change in the quality of evidence. 
Objectives: To determine the change in quality of evidence in updates of Cochrane reviews 
that were initially published between 1st January 2013 and 30th June 2014. 
Methods: We searched the Cochrane Database of Systematic Reviews on March 20th, 2020 
to identify which of the reviews from the initial (2013/14) sample have been updated. Using 
the same methods to determine the quality of evidence in the previous analysis, we assessed 
the quality of evidence for the first listed primary outcomes in the updated reviews.  
Results: Of the 608 reviews in the original sample, 154 had been updated with 151 
presenting available data for both original and updated SRs (24.8%). The updated reviews 
included: 15 (9.9%) with high quality evidence, 56 (37.1%) with moderate, 47 (31.1%) with 
low, and 33 (21.9%) with very low-quality evidence. No change in the GRADE quality of 
evidence was found for most (103, 68.2%) of the updated reviews. Of the 48 reviews with a 
change in GRADE rating (58.3%) were downgraded, mostly to low or very low. The quality 
of evidence rating improved in 20 (41.7%), although only 6 reviews were promoted to high 
quality.  
Conclusions: Updated systematic reviews continued to suggest that only a minority of 
outcomes for healthcare interventions are supported by high-quality evidence. The quality of 
the evidence did not consistently improve or worsen in updated reviews.  
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What is new? 
Key findings 
 The quality of evidence (according to GRADE) supporting the main finding changes 
in about a quarter of updated reviews. 
 Upgrading of quality of evidence (according to GRADE) for the main outcome is not 
more common than downgrading quality of evidence. 
What this adds to what was known? 
 Quality of evidence does not seem to improve overall with the addition of new 
evidence, at least within the timeframe assessed. 
What is the implication and what should change now? 
 Methods investigating when review updates are likely to change our confidence in the 
estimated outcome effect could inform decisions about whether to update reviews in 
order to save resources. 
 The quality of evidence supporting most healthcare interventions remains low; higher 








Several meta-epidemiological studies have attempted to determine the proportion of 
healthcare interventions that are evidence-based. A 2001 estimate found that about a quarter 
(26.7%) of healthcare interventions whose effectiveness was reported in 160 Cochrane 
Reviews were considered effective, based on the interpretation of the review authors. 1 In 
2007, Garrow claimed that 50% of healthcare treatments have good evidence to support 
them. 2 In the same year, El Dib et al. (2007) found that just 44% of a random selection of 
Cochrane Reviews evaluating interventions suggested that they were likely to be beneficial. 3 
Since these studies were published, the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) system has been introduced offering a less subjective 
way of ranking the quality of evidence. 4 An evaluation of all Cochrane Reviews published 
between January 1, 2013 and June 30, 2014 found that 13.5% of reviews were found to have 
high quality of evidence for the first listed primary outcome according to GRADE.5 High 
quality evidence was more common in updated compared to new reviews and in association 
with pharmacologic than other types of interventions. Even when any outcomes (including 
but not limited to the first listed primary outcome) were considered, only 116/608 (19.1%) of 
the reviews reported at least one outcome with high quality of evidence. 
Most researchers agree that it is important to update systematic reviews so that they 
reflect current knowledge, 6 7 to maximize patient benefits, and to avoid harm. 8 However, 
updated reviews frequently reveal no change in conclusions when compared with the 
original. According to French et al., only about 9% of updated Cochrane Reviews in 2002 
presented a change in conclusion relative to their precursors from 1998. 9 However, the claim 
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that the updates did not overturn results from the original review was based on whether 
review authors stated there was a change in the conclusion of the updated review. 
There is currently no consensus on the timing that would appropriately guide a review 
update and the Cochrane Collaboration’s policy is to update reviews when evidence 
accumulates, based on the availability of new data that would have a meaningful impact on 
the findings and on the importance of the review question. 10 Previous reports have identified 
a median time required for an update of a systematic review of approximately 5.5 years. 11 It 
was therefore considered appropriate to assess whether reviews conducted back in 2013- 
2014 (Fleming et al., 2016) have been updated by early 2020, and if so, whether there are 




The primary objective was to determine whether updates from a previous sample of 
systematic reviews resulted in a different quality evidence, as assessed by GRADE. The 
secondary objectives were to determine whether there is a difference in the change of quality 




2.1. Eligibility criteria 
 
 7 
We included any Cochrane Review that was an update of a Cochrane Review published 
in the (01/01/2013—30/06/2014) parent sample of reviews which included a GRADE 
assessment. 
 
2.2. Information sources 
 
Cochrane Database of Systematic Reviews: https://www.cochranelibrary.com/cdsr/reviews. 
 
2.3. Search strategy 
 
We searched the Cochrane Database of Systematic Reviews to identify the reviews 
from the original sample which had updates. The most recent search was on March 20th, 
2020. 
 
2.4. Data sources and searches 
 
One author (DK) retrieved the systematic reviews from the original (2013/14) sample 
and piloted the extraction form with one other author (JH). One author (DK) checked whether 
an update had been published and extracted data for the updated review. Other authors (JH, 
ML, PF, HW) were second extractors (all records were checked by two authors). All 
discrepancies were resolved by discussion. 
 
2.5. Data items 
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Extracted information included: titles, corresponding author name and email, Cochrane 
Review Group, year of publication, country, study design, intervention (and intervention 
category), control and outcome. In relation to the GRADE Summary of Findings tables 
(SoF), the following were recorded for the first listed outcome: category of intervention 
(including surgical, pharmacologic, behavioural or medical treatments, and diet or exercise 
interventions). In brief, “behavioural” interventions pertained to psychological treatment, 
psychotherapy, cognitive training, group therapy; “diet or exercise” interventions largely 
related to training exercise, physiotherapy, rehabilitation, dietary modification; “medical 
treatments” were summarized by electronic optical/ hearing aids, appliance/ device use for 
dental treatment, ultrasound or other radiography and medical interventions not related to 
surgical or pharmacologic approaches; type of outcomes (objective, such as mortality or 
outcomes assessed with an instrument or pre-specified measurable criteria; or subjective) and 
overall GRADE ranking with reasons for downgrade or upgrade. In cases where multiple 
Summary of Findings tables within the same review existed for the primary outcome, we 
considered only the one listed first. In cases where no high-quality evidence was recorded for 
the first listed primary outcome, we documented whether any other outcome was rated as 
high and, if so, whether this was a primary (but not first listed) one. 
We reported whether the Cochrane review authors concluded that the experimental 
intervention should be used in clinical or public health practice or not. This information was 
obtained from the conclusions section in the review abstract and the body of the review 
(subsections “implications for practice” and/ or “implications for research”), following the 
original strategy implemented in the parent study.5 Examples of positive interpretations were: 
“Buprenorphine should be supported as a medication to use,” and in the “Implications for 
research or practice” section: “There does not appear to be any need for further randomized 





The primary outcome was the change in quality of the evidence for the primary 
outcome in updated Cochrane Reviews compared with reviews published in an earlier 
(01/01/2013—30/06/2014) parent sample. The secondary outcomes were the proportion of 
reviews in the updated sample that have high, moderate, low, or very low-quality evidence. 
We also assessed the review authors’ interpretation of results (as reported in the review 
conclusions), for high quality evidence and reports of statistically significant results. 
 
2.7. Data synthesis and analysis 
 
Descriptive statistics on year of publication of the update, as well as the time interval 
between the publication in the parent sample and the update were calculated. In addition, 
frequency of type of intervention and related outcome were calculated for the reviews that 
had been updated until the date of search. For studies that were updated, a change in the 
rating of evidence, if present, and its direction was recorded (downgrade, upgrade). Data 
accumulation for the review update was also recorded, based on number of studies/ 
participants included in the review’s first listed outcome.  
We reported actual proportions (n/N) as well as percentages of reviews reporting high, 
moderate, low or very low-quality evidence in the new sample of reviews. The quality of 
evidence according to GRADE in the new subset of reviews with updates was tabulated 
across the respective versions in the parent sample in a matched 4 x 4 table. We then 
compared the difference in quality of evidence between the original and updated sample. We 
used the 2-sided exact signed-rank test to assess upgrades/downgrades between the original 
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and updated reviews. We also performed a Stuart-Maxwell marginal homogeneity test. In 
addition, we performed assessments considering the presence of high-quality rating for any 
main outcome rather than just the first listed primary outcome. 
For outcomes reported in the Summary of Findings table to be at the extremes (very 
low or high) of evidence quality, we reported the distribution of statistically significant 
results (P<0.05 or 95% confidence interval (CI) excluding the null), along with the reviewers’ 
interpretation of the value of the intervention in clinical practice.  
All statistical analyses were conducted with STATA software 15.1 (Stata Corporation, 
College Station, TX, USA) and R Software version 3.6.1 (R Foundation for Statistical 
Computing, Vienna, Austria). 
 
2.8. Protocol Amendments 
 
In the protocol, we planned a subgroup analyses by disease area, intervention type, and 
Cochrane Review Group. However, data for subgroups were deemed too sparse to allow for 





3.1. Search results 
 
Of the 608 reviews in the original sample, 154 (25.3%) had been updated, and 151 of 
those presented information on GRADE quality of evidence for both initial and updated 
reviews so were retained for further assessment (Figure 1). The median year of the update 
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was 2017 (interquartile range= 2, range: 2015 to 2020), with a median of 4 years (IQR= 2, 
range: 2 to 7 years) after the original review was published. Among the updated reviews, the 
original version with which it was compared (published in 2013-2014) was already an update 
of a previous version for 69 (45.7%) reviews.   
Most reviews in the present samples of Cochrane updates pertained to pharmacological 
interventions (n=82; 54.4%), followed by behavioural (n=24; 15.9%) and surgical (n= 23; 
15.2%) interventions, the use of medical devices (n=15; 9.9%), and diet- or exercise- related 
interventions (n=7; 4.6%). In most of the reviews, the primary outcome considered was 
classified as objective (127/151; 84.1%). 
 
3.2. Quality of evidence in the entire updated (2020) sample 
Within the 151 updated reviews, 15 (9.9%) had high quality evidence supporting the 
first listed primary outcome, 56 (37.1%) moderate, 47 (31.1%) low, and 33 (21.9%) very low. 
Compared with the original sample, there was a reduction in the proportion of reviews with 
high quality. However, this reduction was not statistically significant (see below). GRADE 
ranking comparison between the original and updated reviews are presented in Table 1, Table 
2, and Figure 2. 
 
Table 1. Summary of Review Quality from Updated and Original Samples 










2020 15 (9.9) 56 (37.1) 47 (31.1) 33 (21.9) 
2013/14 82 (13.5) 187 (30.8) 193 (31.7) 146 (24) 
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Table 2. Change in quality of evidence across 151 reviews with updates for primary 
outcomes (the numbers below the diagonal are those which were upgraded, while those 
above were downgraded). 
 
 























































9 (60.0) 4 (7.1) 7 (14.9) 0 (0.0) 20 (13.2) 
Moderate 
N (%) 
4 (26.7) 40 (71.4) 8 (17.0) 3 (9.1) 54 (35.8) 
Low 
N (%) 
2 (13.3) 8 (14.3) 30 (63.8) 6 (18.2) 47 (31.1) 
Very Low 
N (%) 
0 (0.0) 4 (7.2) 2 (4.3) 24 (72.7) 30 (19.9) 
 
Total 15 (100.0) 56 (100.0) 47 (100.0) 33 (100.0) 151 (100.0) 
 
3.3. Change in quality of evidence 
 
3.3.1. Change in quality of evidence for primary outcome 
 
Most (103/151, 68.2%) of the updated reviews reported no change in the GRADE 
quality of evidence compared with the initial sample (blue diagonal in Table 1). Of the 
reviews with unchanged grading, 9 (8.7%) reported high-quality evidence, 40 (38.8%) had 
moderate, 30 (29.2%) low, and 24 (23.3%) very low quality of evidence. In 63 of the 103 
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updated reviews without a changed GRADE rating (61.2%), there was no additional data 
included in the updates, whereas in the remaining 35 reviews, more data had been added. In 5 
reviews (4.9%) the update contained fewer primary studies than the original, but there was 
still no change in the GRADE rating. There was no statistical difference in the change in the 
quality of the evidence ratings (P= 0.30) between the original and updated reviews. The P-
value for the marginal homogeneity test was 0.55. 
A change in GRADE rating was reported in 48 of the 151 updated reviews. Twenty-
eight of these (58.3%) were downgraded, mostly (24/28) to low or very low. Of first-listed 
primary outcomes initially recorded as having “high” quality evidence (n=15), 11 were 
downgraded to low (n=7) or moderate (n=4) quality of evidence. Twenty of the 48 reviews 
that had a changed GRADE involved an upgrade. Of those, 6 were upgraded to “high”. 
Thirty of the 48 trials (62.5%) that had a changed GRADE rating included additional 
data. Among these, 15 resulted in upgrades, and 15 in downgrades. In 16 (33.3%) the 
changed GRADE rating was not based on new data. In two updated reviews (4.2%), changes 
were based on fewer data for the primary outcome of interest; both resulted in upgrades. 
Finally, 16 out of 48 reviews with a change in GRADE rating, were based on the same 
included data (33.3%).   
 
3.3.1. Change in quality of evidence for other outcomes (those that were not first listed non-
primary) 
Of the 151 updated reviews which did not present high quality of evidence for the first-
listed primary outcome, 19 had other (non-primary, or primary but not first listed) outcomes 
that were ranked as high-quality. Ten of these involved primary outcomes. The overall 
quality of the evidence in the updates for any outcome was high in 34 out of 151 updated 
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reviews (22.5%). Again, we did not find a significant difference between the original and 
updated reviews for this comparison (P=0.72). The P-value by the marginal homogeneity test 
was P= 0.32. 
 
3.4. Review authors’ interpretations and statistical significance of results 
 
Among extreme evidence quality ratings (very low and high), 8/33 (24.2 %) of those 
with very low quality and 10/15 (66.7 %) of those with high quality evidence had statistically 
significant results for at least one outcome in the updated sample. Across all 151 updated 
reviews, only 2 had high quality evidence, statistically significant results, and a favourable 




4.1. Summary of findings 
 
One-quarter of the reviews in our sample had been updated over the 6-7-year period. Of 
those, a third reported a change in GRADE ratings. There was no evidence of GRADE 
ratings being more likely to improve than worsen in these topics, with a weak trend towards 
worsening. 
In keeping with a previous finding that 23% of Cochrane Reviews were out of date 
within two years, 11 our study may also show that Cochrane Reviews are not updated very 
frequently.12 Specifically, we observed a median hiatus for publication of the updated review 
of 4 years among the reviews that were updated and most reviews were not even updated at 
all. 
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In some cases, downgrading of evidence quality was related to the new Risk of Bias 
assessment forming the basis for the GRADE framework. Risk of Bias assessments have 
become stricter in the new Cochrane Handbook and might have led to automatic 
downgrading due to items that had not been rated before or rated differently. This seems to be 
reflected in the fact that in approximately one-third of the reviews where the rating changed 
(16/48), there was no new data included in the review regarding the primary outcome of 
interest. Nevertheless, 81.3% (13/16) of the reviews with no new data reported worsening of 
evidence quality. 
Another explanation for different GRADE ratings for updated reviews that had no new 
data is potential inconsistency in the way the way GRADE is applied. One study found 
variability in the way GRADE is applied leading to different conclusions about strength of 
evidence. 13 Another study found low agreement among systematic reviewers using the 
Cochrane Risk of Bias tool (which influences the GRADE rating). 14 This may partially 
explain why two of the updated reviews whose evidence quality was upgraded were based on 
fewer studies than the original. The omitted studies also reduced imprecision or risk of bias. 




The extent to which our findings are generalisable needs to be discussed. Our sample of 
reviews from 2013 and 2014 may not be representative of all medical evidence. It pertains to 
topics where either a new review was published at that time or it was deemed that an update 
was then indicated. Similarly, the reviews that were updated may not be representative of the 
original sample. Reviews which were not updated may have been less likely to require 
updating. If so, the proportion of changes in GRADE ratings we found may have been even 
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exaggerated. If we account also for this selection process, the results suggest that 
improvements in the quality of evidence in different medical topics are even more 
uncommon. Finally, we had a relatively small number of updated reviews, thus we could not 
meaningfully explore whether improvements in the quality of evidence are more or less likely 
in specific fields. However, no consistent patterns were observed for the very few reviews 
(n=6) where evidence was upgraded to high quality. 
In addition, our conclusions assumed that GRADE is sensitive enough to detect 
changes in evidence quality; this may not be solely the case. GRADE only has four 
categories, and were there additional categories, we may have detected a change in quality in 
a greater number of reviews. On top of that, GRADE assessments may suffer from 
inadequate interrater reliability, while evidence exists about training of review authors and/ or 
duplicate assessments on the use of GRADE, for an improved quality of the evidence 
evaluation approach.17 On the other hand, a more sensitive evidence-rating tool could also be 
more likely to detect noise. More generally, our findings assumed that the GRADE ratings by 
the original review authors were reliable (and, more generally, that GRADE is reliable). To 
overcome this limitation, a re-grading of the original and updated reviews would have to be 




Updating Cochrane systematic reviews does not change the fact that only a minority of 
outcomes for healthcare interventions are supported by high quality evidence. In spite of 
having additional data, most reviews were not updated over the time period of our assessment 
with the majority of updates not resulting in a change in the quality of the evidence. To avoid 
research waste, it should be investigated whether it is possible to decide in advance whether 
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updating a review will result in a change in results. Effects of medical interventions 
supported by high quality evidence, statistically significant results, and favourable 
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Figure 1. Study selection and GRADE of evidence breakdown 
 
 
 
 
